Harvard researchers have created an antibiotic that can overcome many drug-resistant infections.

Researchers at the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology are engineering synthetic antibiotics that directly target bacteria which cause lower respiratory tract and skin and soft tissue infections.

A team of Harvard and Sloan Kettering scientists has developed compounds that can target and degrade proteins associated with acute myeloid leukemia (AML) and nearly doubled the life expectancy of mice with cancer in laboratory tests.

TFome technology, advanced through Blavatnik Biomedical Accelerator, may contribute to new cell therapies